MARKET

TLGT

TLGT

Teligent Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3900
+0.0080
+2.09%
After Hours: 0.3800 -0.01 -2.56% 19:14 09/17 EDT
OPEN
0.3773
PREV CLOSE
0.3820
HIGH
0.3936
LOW
0.3720
VOLUME
3.53M
TURNOVER
--
52 WEEK HIGH
1.600
52 WEEK LOW
0.3700
MARKET CAP
36.20M
P/E (TTM)
-0.0757
1D
5D
1M
3M
1Y
5Y
Teligent Pharma Issued Voluntary Recall Of Lidocaine Topical Solution 4%, Cites 'Super Potency'
-Reuters
Reuters · 08/30 16:43
BRIEF-FDA Says Teligent Pharma, Inc.’S Issues Voluntary Recall Of Lidocaine Hcl Topical Solution 4% (Lot # 14218, Exp. 09/2022) Due To Super Potency
reuters.com · 08/30 16:42
FDA Says Teligent Pharma Has Not Received Any Reports Of Adverse Events Related To Co. Recall
-Reuters
Reuters · 08/30 16:41
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 11:37
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
Stocks That Hit 52-Week Lows On Monday
  On Monday morning, 207 companies hit new 52-week lows.
Benzinga · 08/16 14:12
Teligent Q2 EPS $(0.14) Misses $(0.13) Estimate, Sales $10.43M Miss $10.49M Estimate
Teligent (NASDAQ:TLGT) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.13) by 7.69 percent. This is a 90.91 percent increase over losses of $(1.54) per share from the
Benzinga · 08/16 11:07
-- Earnings Flash (TLGT) TELIGENT Reports Q2 Loss $-0.14
MT Newswires · 08/16 07:22
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TLGT. Analyze the recent business situations of Teligent Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TLGT stock price target is 1.000 with a high estimate of 1.000 and a low estimate of 1.000.
EPS
Institutional Holdings
Institutions: 73
Institutional Holdings: 25.19M
% Owned: 27.13%
Shares Outstanding: 92.82M
TypeInstitutionsShares
Increased
6
1.54M
New
7
524.88K
Decreased
6
2.27M
Sold Out
8
183.70K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.40%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Non-Executive Chairman/Independent Director
John Celentano
President/Chief Executive Officer/Director
Timothy Sawyer
Chief Financial Officer
Ernest De Paolantonio
Executive Vice President/Secretary
Philip Yachmetz
Independent Director
Carole Ben-Maimon
Independent Director
William Marth
Independent Director
Carter Pate
Independent Director
Thomas Sabatino
No Data
About TLGT
Teligent, Inc. is a generic pharmaceutical company. The Company is focused on the development, manufacturing and marketing of a portfolio of generic pharmaceutical products under its own label and private label for other pharmaceutical companies in topical, injectable, complex and other dosage forms. It also provides contract development and manufacturing services to the prescription and over-the-counter (OTC) pharmaceutical and cosmetic markets. Under the Company's own label, it markets and sells generic topical, and generic and branded generic injectable pharmaceutical products in the United States and Canada. In the United States, the Company markets approximately 37 generic topical pharmaceutical products and one branded injectable pharmaceutical product. In Canada, it markets approximately 24 generic injectable, one generic topical and three generic ophthalmic products.

Webull offers kinds of Teligent Inc (NEW JERSEY) stock information, including NASDAQ:TLGT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TLGT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TLGT stock methods without spending real money on the virtual paper trading platform.